COVID Patient Infusion for Monoclonal antibody therapy (bamlanivimab/etesevimab) has been approved under an FDA Emergency Use Authorization (EUA) for the treatment of COVID-19 in non-hospitalized adults with mild to moderate symptoms and who are at high risk of needing hospitalization for severe COVID-19. High risk patients include those who meet any of the following: age 65 or older, ages 55 to 64 or older with hypertension, heart disease, or respiratory disease, or patients 18 and older who have a BMI of 35 or more, diabetes, kidney disease, immunosuppressive disease, or takes medications that weaken the immune system. The greatest benefit to the treatment is within five days of COVID-19 symptom onset. If it has been more than 10 days since symptoms began patients are ineligible for the treatment.
Appointments for infusion are available at McLeod Regional Medical Center, McLeod Health Clarendon, McLeod Health Seacoast, McLeod Health Carolina Forest and McLeod Health Loris. Healthcare providers may use the referral form below to begin the process of scheduling patients for treatment.
McLeod Health is screening patients 55 and older who have been tested at a McLeod Health Specimen Collection Unit or Emergency Department and are positive for COVID-19 for possible treatment and contacting these patients with information about the therapy.
If you are a healthcare provider:
If you are a patient and do not have a primary care provider: